FAP and neoplasm: Finally, in the work by Fendler et al. [24], up to four cycles of [90Y]DOTA-FAPi-46 RLT were administered to patients with progressive metastatic malignancy with adequate haematopoiesis and high FAP expression levels (defined as [68Ga]Ga-DOTA-FAPi-46 SUVmax ≥ 10 in >50% of the tumour).